文献速递胸部CT

欧洲低剂量CT肺癌筛查:多项独立筛查试验的优势与不足

Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials.
PubMed 文献 · Clin Radiol · 2017-02-04

本文综述欧洲多项独立低剂量CT肺癌筛查试验,讨论高危人群预选、筛查间隔、阳性结节定义及基于LDCT的肺癌风险再分层等关键问题。UKLS试验显示综合简易风险模型可筛选5年肺癌风险5%的人群;MILD试验报告两年一次与每年一次筛查效率相当且LDCT总检查数显著减少;NELSON试验引入基线结节容积定量与体积倍增时间评估进展。戒烟仍是降低死亡率的最合适策略,应作为任何肺癌筛查项目的组成部分。

要点

  • UKLS试验显示综合简易风险模型可用于筛选5年肺癌风险5%的人群。
  • MILD试验报告两年一次与每年一次筛查效率相当,且LDCT总检查数显著减少。
  • NELSON试验采用基线结节容积定量与体积倍增时间评估结节进展。

核心结论

  • 欧洲独立多样筛查策略虽缺乏死亡率下降的统计学证据,但为筛查复杂性提供多视角,并在成本效果与危害-获益平衡方面给出改进提示;戒烟仍是降低死亡率的最合适策略,必须作为任何肺癌筛查项目的组成部分。

研究设计与样本

  • 综述欧洲多项独立低剂量CT肺癌筛查试验,涉及UKLS、MILD、NELSON等试验,讨论高危人群预选、筛查间隔、阳性发现定义及基于LDCT的肺癌风险再分层。

诊断标准与关键数值

  • UKLS试验采用综合简易风险模型筛选5年肺癌风险5%的人群。
  • NELSON试验在基线采用结节容积定量,并以体积倍增时间评估进展。
  • MILD试验报告两年一次与每年一次筛查效率相当,且LDCT总检查数显著减少。

临床应用与阅片要点

  • 高危人群预选可采用综合简易风险模型(如UKLS的5年风险5%模型)。
  • 筛查间隔可考虑两年一次以在效率相当情况下减少LDCT总检查数,原文为MILD试验报告。
  • 结节评估可采用基线容积定量与体积倍增时间判断进展,原文为NELSON试验引入。
  • 戒烟应作为任何肺癌筛查项目的组成部分。

局限性

  • 原文指出目前缺乏关于死亡率下降的统计学证据。
  • 基于生物学采样的主观风险预测正在研究中。
  • 基于LDCT表现的定性或定量检测后风险细化正在研究中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

A North American trial reported a significant reduction of lung cancer mortality and overall mortality as a result of annual screening using low-dose computed tomography (LDCT). European trials prospectively tested a variety of possible screening strategies. The main topics of current discussion regarding the optimal screening strategy are pre-test selection of the high-risk population, interval length of LDCT rounds, definition of positive finding, and post-test apportioning of lung cancer risk based on LDCT findings. Despite the current lack of statistical evidence regarding mortality reduction, the European independent diverse strategies offer a multi-perspective view on screening complexity, with remarkable indications for improvements in cost-effectiveness and harm-benefit balance. The UKLS trial reported the advantage of a comprehensive and simple risk model for selection of patients with 5% risk of lung cancer in 5 years. Subjective risk prediction by biological sampling is under investigation. The MILD trial reported equal efficiency for biennial and annual screening rounds, with a significant reduction in the total number of LDCT examinations. The NELSON trial introduced volumetric quantification of nodules at baseline and volume-doubling time (VDT) for assessment of progression. Post-test risk refinement based on LDCT findings (qualitative or quantitative) is under investigation. Smoking cessation remains the most appropriate strategy for mortality reduction, and it must therefore remain an integral component of any lung cancer screening programme.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Silva M, Pastorino U, Sverzellati N, et al. Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials. Clin Radiol. 2017. PMID: 28168954. doi:10.1016/j.crad.2016.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。